121 related articles for article (PubMed ID: 30293449)
1. Extended-release morphine sulfate and naltrexone hydrochloride (EMBEDA): naltrexone-associated withdrawal and abuse-related effects in patients with chronic pain and recreational opioid users.
Setnik B; Sommerville KW; Pixton GC; Webster L
Curr Med Res Opin; 2019 Mar; 35(3):503-512. PubMed ID: 30293449
[TBL] [Abstract][Full Text] [Related]
2. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
Setnik B; Roland CL; Goli V; Sommerville K; Webster L
J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
[TBL] [Abstract][Full Text] [Related]
3. Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users.
Setnik B; Sommerville K; Goli V; Han L; Webster L
Pain Med; 2013 Aug; 14(8):1173-86. PubMed ID: 23745947
[TBL] [Abstract][Full Text] [Related]
4. Safety of EMBEda (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of postmarketing adverse events during the first year.
Badalamenti VC; Buckley JW; Smith ET
J Opioid Manag; 2012; 8(2):115-25. PubMed ID: 22616317
[TBL] [Abstract][Full Text] [Related]
5. Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature.
Ruan X; Chen T; Gudin J; Couch JP; Chiravuri S
J Opioid Manag; 2010; 6(4):300-3. PubMed ID: 20862910
[TBL] [Abstract][Full Text] [Related]
6. Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability.
Johnson F; Setnik B
Pain Physician; 2011; 14(4):391-406. PubMed ID: 21785483
[TBL] [Abstract][Full Text] [Related]
7. Safety profile of extended-release morphine sulfate with sequestered naltrexone hydrochloride in older patients: pooled analysis of three clinical trials.
Setnik B; Pixton GC; Webster LR
Curr Med Res Opin; 2016; 32(3):563-72. PubMed ID: 26695349
[TBL] [Abstract][Full Text] [Related]
8. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users.
Webster LR; Johnson FK; Stauffer J; Setnik B; Ciric S
Drugs R D; 2011 Sep; 11(3):259-75. PubMed ID: 21902287
[TBL] [Abstract][Full Text] [Related]
9. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study.
Stauffer J; Setnik B; Sokolowska M; Romach M; Johnson F; Sellers E
Clin Drug Investig; 2009; 29(12):777-90. PubMed ID: 19888784
[TBL] [Abstract][Full Text] [Related]
10. Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users.
Setnik B; Goli V; Levy-Cooperman N; Mills C; Shram M; Smith I
Pain Res Manag; 2013; 18(4):e55-62. PubMed ID: 23936895
[TBL] [Abstract][Full Text] [Related]
11. Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing.
Smith HS
Expert Opin Pharmacother; 2011 May; 12(7):1111-25. PubMed ID: 21470065
[TBL] [Abstract][Full Text] [Related]
12. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers.
Johnson FK; Stark JG; Bieberdorf FA; Stauffer J
Clin Ther; 2010 Jun; 32(6):1149-64. PubMed ID: 20637968
[TBL] [Abstract][Full Text] [Related]
13. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain.
Katz N; Hale M; Morris D; Stauffer J
Postgrad Med; 2010 Jul; 122(4):112-28. PubMed ID: 20675975
[TBL] [Abstract][Full Text] [Related]
14. Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.
Setnik B; Bass A; Bramson C; Levy-Cooperman N; Malhotra B; Matschke K; Geoffroy P; Sommerville KW; Wolfram G
Pain Med; 2017 Jun; 18(6):1077-1088. PubMed ID: 27550954
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of ALO-02 (oxycodone hydrochloride and sequestered naltrexone hydrochloride) extended-release capsules in older patients: a pooled analysis of two clinical trials.
Wilson JG; Bass A; Pixton GC; Wolfram G; Rauck RL
Curr Med Res Opin; 2020 Jan; 36(1):91-99. PubMed ID: 31456431
[No Abstract] [Full Text] [Related]
16. Sustained-release morphine sulfate with sequestered naltrexone for moderate to severe pain: a new opioid analgesic formulation and beyond.
Ruan X
Expert Opin Pharmacother; 2011 May; 12(7):999-1001. PubMed ID: 21470064
[TBL] [Abstract][Full Text] [Related]
17. Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.
Backonja M; Webster LR; Setnik B; Bass A; Sommerville KW; Matschke K; Malhotra BK; Wolfram G
Am J Drug Alcohol Abuse; 2016 Sep; 42(5):539-549. PubMed ID: 27211522
[TBL] [Abstract][Full Text] [Related]
18. Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients.
Cicero TJ; Mendoza M; Cattaneo M; Dart RC; Mardekian J; Polson M; Roland CL; Schnoll SH; Webster LR; Park PW
Postgrad Med; 2019 Apr; 131(3):225-229. PubMed ID: 30794760
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
20. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety.
Katz N; Sun S; Johnson F; Stauffer J
J Pain; 2010 Apr; 11(4):303-11. PubMed ID: 19944650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
